RxDoctor Payments Data

Katherine Kavanaugh

Critical Care Medicine · Cedar Rapids, IANPI 1821058306

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.7% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations.

$1,869in general payments, 2019–2025

Across 32 payments — averaging $58.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • United Therapeutics Corporation$400
  • Actelion Pharmaceuticals US, Inc.$199
  • Bayer$182
  • Medtronic$159
  • Boston Scientific$159
  • Abbott$145
  • plus $626 from 9 others

What the payments were for

  • Food & beverage$1,864100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,869 in reported general payments places this provider in the 80th percentile of 33 critical care medicine providers in Iowa.

See all critical care medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$28,674
Medicare patients
150
Services billed
236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OpsumitMacitentan97$1,245,803
Tyvaso DpiTreprostinil28$651,873
AdempasRiociguat46$578,171
Ambrisentan61$122,616
EliquisApixaban112$88,800
XareltoRivaroxaban43$52,039
Sildenafil Citrate41$10,421
Tadalafil16$9,124
Bumetanide171$8,441
Potassium Chloride150$3,294
Isosorbide Dinitrate54$1,673
Metoprolol Succinate175$1,495
Albuterol Sulfate HfaAlbuterol Sulfate37$920
Torsemide29$900
Losartan Potassium111$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit$199$1,245,80397 claims
BayerAdempas$182$578,17146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 33 critical care medicine providers in Iowa.

Other critical care medicine in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →